Pfizer Inc. will hand over the development of a tumor necrosis factor-like ligand 1A (TL1A) inhibitor to Roivant Sciences Ltd., which will form a new "vant" around the asset, the companies announced on 1 December. Pfizer's PF-06480605, now renamed RVT-3101, is in Phase IIb development in ulcerative colitis, with data expected in the first half of 2023.
The announcement marks the second time this year Pfizer has partnered with Roivant in a similar arrangement for a single...